Statin Use Decreases the Risk of Metachronous Gastric Cancer in Patients without Helicobacter pylori Infection.
Statin Use Decreases the Risk of Metachronous Gastric Cancer in Patients without Helicobacter pylori Infection.
复制标题
DOI：
10.3390/cancers13051020
复制
发表时间：
2021-03-01
期刊：
影响因子：
5.2
通讯作者：
Kim JJ
中科院分区：
文献类型：
--
作者：
Kwon TJ;Kim TJ;Lee H;Min YW;Min BH;Lee JH;Kim JJ
他汀类药物已被证明可以降低胃癌（GC）的风险。关于它们对H. pylori阴性的早期胃癌（EGC）内镜切除术后患者。在这项队列研究中，EGC患者没有H。pylori感染，我们发现他汀类药物与胃癌复发风险的降低有关。他汀类药物的使用与异时性胃癌的风险之间存在剂量反应关系。本研究提供了他汀类药物作为异时性胃癌的化学预防剂在接受内镜下切除术的EGC患者中的额外益处的证据。以前的研究表明，他汀类药物降低胃癌的风险;然而，他们的作用还没有得到充分的研究，在没有幽门螺杆菌感染的患者。我们的目的是研究他汀类药物是否能降低H.因早期胃癌（EGC）接受内镜切除术的幽门阴性患者。2007年1月至2016年12月招募的2153例患者的回顾性数据，无H. pylori感染的患者进行分析。异时性胃癌定义为内镜切除术后至少1年内新发的胃癌。在随访期间使用他汀类药物至少28天的患者被视为他汀类药物使用者。在中位随访5年（四分位距，3.5-6.2）期间，165例（7.6%）患者发生异时性GC。在多变量考克斯回归分析中，他汀类药物使用是与GC复发相关的独立因素（校正风险比（HR），0.46; 95%置信区间（CI），0.26-0.82）。此外，随着病程的延长，胃癌的风险降低（<3年：HR 0.40，95% CI 0.14-1.13; ≥3年：HR 0.21，95% CI 0.05-0.90; p趋势= 0.011）和他汀类药物剂量（累积限定日剂量（cDDD）< 500：HR 0.45，95% CI 0.16-1.28; cDDD ≥ 500：HR 0.19，95% CI 0.04-0.80; p趋势= 0.008）。他汀类药物的使用与胃癌复发风险降低相关。幽门螺杆菌阴性的EGC切除患者的剂量反应关系。
Statins have been shown to reduce the risk of gastric cancer (GC). Little is known about their effects on metachronous GC in H. pylori negative patients after endoscopic resection for early gastric cancer (EGC). In this cohort study among patients with EGC without H. pylori infection, we found that statins are associated with a decrease in the risk of recurrence of GC. There was a dose-response relationship between the use of statins and the risk of metachronous GC. This study provides evidence about the additional benefits of statins as chemopreventive agents against metachronous GC among patients who underwent endoscopic resection for EGC. Previous studies have shown that statins reduce the risk of gastric cancer; however, their role has not been adequately studied in patients without Helicobacter pylori infection. We aimed to investigate whether statins reduced the risk of metachronous gastric cancer (GC) in H. pylori-negative patients who underwent endoscopic resection for early gastric cancer (EGC). Retrospective data of 2153 patients recruited between January 2007 and December 2016, with no H. pylori infection at baseline, who underwent resection for EGC, were analyzed. Metachronous GC was defined as a newly developed GC at least 1 year after endoscopic resection. Patients who used statins for at least 28 days during the follow-up period were considered as statin users. During a median follow-up of 5 years (interquartile range, 3.5–6.2), metachronous GC developed in 165 (7.6%) patients. In the multivariate Cox regression analysis, statin use was an independent factor associated with GC recurrence (adjusted hazard ratio (HR), 0.46; 95% confidence interval (CI), 0.26–0.82). Moreover, the risk of GC reduced with increasing duration (<3 years: HR 0.40, 95% CI 0.14–1.13; ≥3 years: HR 0.21, 95% CI 0.05–0.90; p trend = 0.011) and the dose of statin (cumulative defined daily dose (cDDD) < 500: HR 0.45, 95% CI 0.16–1.28; cDDD ≥ 500: HR 0.19, 95% CI 0.04–0.80; p trend = 0.008) in the propensity score-matched cohort. Statin use was associated with a lower risk of GC recurrence in H. pylori-negative patients with resected EGC in a dose-response relationship.
登录
查看更多内容
影响因子：
3.8
作者：
Cheung, Ka Shing;Chan, Esther W.;Leung, Wai K.
通讯作者：
Leung, Wai K.
影响因子：
11.2
作者：
Cao Z;Fan-Minogue H;Bellovin DI;Yevtodiyenko A;Arzeno J;Yang Q;Gambhir SS;Felsher DW
通讯作者：
Felsher DW
影响因子：
9.3
作者：
Min, Byung-Hoon;Kim, Eun Ran;Kim, Jae J.
通讯作者：
Kim, Jae J.
影响因子：
8.8
作者：
Follet J;Corcos L;Baffet G;Ezan F;Morel F;Simon B;Le Jossic-Corcos C
通讯作者：
Le Jossic-Corcos C
影响因子：
3.7
作者：
Cholesterol Treatment Trialists' (CTT) Collaboration;Emberson JR;Kearney PM;Blackwell L;Newman C;Reith C;Bhala N;Holland L;Peto R;Keech A;Collins R;Simes J;Baigent C
通讯作者：
Baigent C